Clinical Trial Update: A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises [Phase 3]

View source ↗

Summary

Pfizer's Phase 3 study evaluating a single dose of inclacumab to reduce hospital readmissions in sickle cell disease patients with recurrent vaso-occlusive cris…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Inclacumab

Snippet

Sponsor: Pfizer | Conditions: Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Status: TERMINATED | Results posted: 2024-12-11